513 related articles for article (PubMed ID: 16182573)
21. Levetiracetam in refractory epilepsy: a prospective observational study.
Mohanraj R; Parker PG; Stephen LJ; Brodie MJ
Seizure; 2005 Jan; 14(1):23-7. PubMed ID: 15642496
[TBL] [Abstract][Full Text] [Related]
22. Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy.
Shukla G; Gupta A; Agarwal P; Poornima S
Epilepsy Behav; 2016 Nov; 64(Pt A):216-218. PubMed ID: 27756024
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial.
Tonekaboni SH; Ghazavi M; Karimzadeh P; Mahvelati F; Ghofrani M
Epilepsy Res; 2010 Aug; 90(3):273-7. PubMed ID: 20619606
[TBL] [Abstract][Full Text] [Related]
25. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).
Borggraefe I; Bonfert M; Bast T; Neubauer BA; Schotten KJ; Maßmann K; Noachtar S; Tuxhorn I; May TW; Heinen F;
Eur J Paediatr Neurol; 2013 Sep; 17(5):507-14. PubMed ID: 23642492
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities.
Huber B; Bömmel W; Hauser I; Horstmann V; Liem S; May T; Meinert T; Robertson E; Schulz L; Seidel M; Tomka-Hoffmeister M; Wagner W
Seizure; 2004 Apr; 13(3):168-75. PubMed ID: 15010054
[TBL] [Abstract][Full Text] [Related]
27. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
28. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
29. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.
Coppola G; Mangano S; Tortorella G; Pelliccia A; Fels A; Romano A; Nardello R; Habetswallner F; Licciardi F; Operto FF; Pascotto A
Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of levetiracetam use following resective surgery in patients with refractory epilepsy: a prospective observational study.
Zeng TF; Li YH; An DM; Chen L; Lei D; Zhang B; Li JM; Zhou D
Epilepsy Res; 2014 Dec; 108(10):1904-11. PubMed ID: 25454502
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study.
Werhahn KJ; Klimpe S; Balkaya S; Trinka E; Krämer G
Seizure; 2011 May; 20(4):305-11. PubMed ID: 21257324
[TBL] [Abstract][Full Text] [Related]
32. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
Delanty N; Jones J; Tonner F
Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
[TBL] [Abstract][Full Text] [Related]
33. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
[TBL] [Abstract][Full Text] [Related]
34. [Experience with levetiracetam in the treatment of childhood refractory epilepsy].
Doumbia-Ouattara M; Bourel-Ponchel E; Le Moing AG; Querne L; Delignières A; de Broca A; Berquin P
Arch Pediatr; 2012 Jan; 19(1):3-8. PubMed ID: 22169571
[TBL] [Abstract][Full Text] [Related]
35. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy.
Tanaka S; Tanaka T
Epileptic Disord; 2013 Jun; 15(2):132-41. PubMed ID: 23774199
[TBL] [Abstract][Full Text] [Related]
36. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
Kinirons P; McCarthy M; Doherty CP; Delanty N
Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
[TBL] [Abstract][Full Text] [Related]
37. Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony.
Kanemura H; Sano F; Sugita K; Aihara M
Seizure; 2013 Jan; 22(1):43-7. PubMed ID: 23127775
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.
Krief P; Li Kan ; Maytal J
J Child Neurol; 2008 May; 23(5):582-4. PubMed ID: 18448575
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
[TBL] [Abstract][Full Text] [Related]
40. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
